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Abstract 
Diabetic peripheral neuropathy (DPN) is one of the most debilitating complications of 
diabetes. DPN is a major cause of foot ulceration and lower limb amputation. Early 
diagnosis and management is a key factor in reducing morbidity and mortality. Current 
techniques for clinical assessment of DPN are relatively insensitive for detecting early 
disease or involve invasive procedures such as skin biopsies. There is a need for less 
painful, non-invasive and safe evaluation methods. Eye care professionals already play 
an important role in the management of diabetic retinopathy; however recent studies 
have indicated that the eye may also be an important site for the diagnosis and 
monitoring of neuropathy. Corneal nerve morphology has been shown to be a promising 
marker of diabetic neuropathy occurring elsewhere in the body, and emerging evidence 
tentatively suggests that retinal anatomical markers and a range of functional visual 
indicators could similarly provide useful information regarding neural damage in 
diabetes – although this line of research is, as yet, less well established. This review 
outlines the growing body of evidence supporting a potential diagnostic role for retinal 
structure and visual functional markers in the diagnosis and monitoring of peripheral 
neuropathy in diabetes. 
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Diabetes mellitus is an increasingly prevalent chronic disease, with a high rate of 
morbidity and mortality worldwide. Reducing diabetes-related morbidity and mortality 
and improving quality of life are major public health goals, which could be assisted by 
earlier disease diagnosis and improved screening protocols for associated 
complications. This could ultimately lead to earlier and more effective management of 
risk factors. Complications can include myocardial infarction, stroke and nephropathy 
as well as retinopathy – a ramification highly familiar to eye-care professionals. 
Another major complication of diabetes is neuropathy – pathological changes affecting 
the neural system throughout the body, which can lead to devastating consequences 
such as lower limb amputation. Neuropathy can also affect the eyes; however its impact 
in this regard is less familiar to health professionals. Although changes to corneal 
structure in diabetes are relatively better characterised,
1, 2
 this review will outline what 
is known about alterations in retinal structure and visual function, which may ultimately 
manifest as a consequence of neural pathology. Conversely, it will explore how retinal 
structure and visual function may hypothetically provide valuable and readily accessible 
early indicators of neuropathy elsewhere in the body.  
 
Diabetes mellitus is defined by the level of hyperglycaemia.
3
 There are two main types 
of diabetes. Type 1 diabetes mellitus, formerly known as insulin-dependant diabetes, is 
characterized by auto-immune destruction of pancreatic beta-cells, leading to a loss of 
insulin secretion. Type 2 diabetes mellitus is the most common form of the disease, 
accounting for over 90 percent of diabetes in Australia.
4
 It involves a combination of 
insulin resistance and impaired insulin secretion. Prevalence increases with age and it is 
strongly associated with obesity. Gestational diabetes is a less common form that occurs 
5 
 
in approximately 7% of all pregnancies and is a major risk factor for later development 
of Type 2 diabetes.
5
 
The prevalence of diabetes increases with age and with population growth
6
 and is higher 
amongst certain racial minorities.
7
 In 2005, over 600,000 Australians (more than 3% of 
the population) were estimated to have established diabetes, with many more cases 
remaining undiagnosed.
8
 Trends for international prevalence of the disease mirror this 
profile.
6
  Diabetes has multiple and wide-ranging health ramifications – however, 
diabetes-related mortality is predominantly caused by cardiovascular disease. Increased 
morbidity is driven by long term microvascular complications; retinopathy is the 
leading cause of premature blindness worldwide,
9
 nephropathy is the most common 
cause of end stage renal failure 
10
 and neuropathy is the leading cause of non-traumatic 
lower limb amputation.
11
 
 
Complications of diabetes 
The incidence of micro-vascular problems such as retinopathy and nephropathy, as well 
as neuropathy, is tightly linked to glycaemic control and to disease duration in both 
Type 1 and Type 2 forms.
12
 Macro-vascular complications of diabetes such as coronary 
artery disease and myocardial infarction are also frequent in this population and risk 
factors like hyperglycaemia, hypertension and dyslipidaemia are thought to play a 
strong role in their incidence.
3
  
 
Peripheral neuropathy – one of the most common complications in the diabetic 
population worldwide
13
 – is characterised by pathology of sensory, motor and 
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autonomic nerves and it has both anatomical and functional repercussions. Its effects are 
primarily evident in the feet and legs where it can result in gait disturbances, 
neuropathic pain, and an increased risk of foot ulceration and subsequent lower limb 
amputation. Although the cardiac manifestations of diabetes are primarily vascular in 
origin, a subset of people with diabetes suffer from autonomic neuropathy, 
14
 which can 
affect heart rate and rhythm, potentially resulting in exercise intolerance and postural 
hypotension. This review focuses primarily on peripheral sensory neuropathy, the most 
common form of neuropathy in diabetes.
15
. 
 
Peripheral nervous system 
The peripheral nervous system (PNS) in humans comprises a range of sensory and 
motor nerve bundles with differing characteristics. In a simplified model, afferent 
(sensory) neurons originate at sensory receptors and serve to inform the central nervous 
system (CNS) of the presence of relevant stimuli, whilst efferent (predominantly motor) 
neurons connect the CNS to muscles to precipitate movement. The somatic subdivision 
of the PNS primarily consists of efferent nerves innervating voluntary skeletal muscle 
but also includes afferent components from the skin, whereas the autonomic subdivision 
innervates involuntary muscles as well as having visceral sensory components (Fig. 1). 
The autonomic system has further sympathetic, parasympathetic and enteric 
subdivisions.
16
  
 
Axon diameter plays an important role in the classification of nerve fibres in the PNS, 
with the thicker myelinated fibres having a faster conduction velocity. Based on this 
7 
 
characteristic, fibres can be categorized into three broad groups. The largest myelinated 
axons belong to group A and these are further delineated into α, β, δ and γ according to 
their function. Group B fibres are primarily myelinated axons of autonomic pre-
ganglionic neurons and they are less well characterized than those in the other groups. 
Group C consists of sensory nerves with relatively small un-myelinated axons.
16
 A 
classification summary of peripheral nerve fibres is provided in Table 1. Diabetic 
peripheral neuropathy can potentially affect nerves from all of these classes. 
 
 
“Figure 1 approximately here” 
“Table 1 approximately here” 
 
Diabetic peripheral neuropathy 
Neuropathy is an important cause of lower limb pathology in diabetes. Pain is a frequent 
and critical end point of peripheral sensory nerve damage and can eventually result in 
depression and other negative psychological outcomes in affected individuals.
17
 Loss of 
sensation is another outcome of advanced neuropathy and contributes significantly to 
the pathogenesis of diabetic foot complications such as ulceration and amputation.
17
  
 
The true prevalence of diabetic peripheral neuropathy (DPN) is uncertain as reported 
data have been derived from varied study designs.
18
 Additionally, epidemiological 
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reports primarily focus on people who have sought medical care for their condition, 
leaving open the possibility of significant numbers of additional sufferers who have not 
attended for assessment and care. This potential incongruity is highlighted by one 
epidemiological report that indicated DPN exists in 20% of the community in general, 
but in 30% of patients who attend hospitals.
19
 Other studies, however, have reported 
prevalences as low as 14% or as high as 54%, with the discrepancy explained by 
differences in study populations and the tests used to evaluate neuropathy.
20, 21
  
 
Several factors are involved in the pathophysiology of diabetic neuropathy. 
Hyperglycaemia, however, is clearly important and is involved at a very early stages of 
diabetes.
22
 At a simplistic level, increased glucose flux through the polyol pathways can 
lead to peripheral nerve damage; the same mechanism can also produce crystalline lens 
changes in the eye.
23
 Oxidative stress and vascular compromise have been postulated as 
further factors potentially underlying DPN.
15
 
 
There are a number of classification systems for diabetic neuropathy, which are 
variously based on anatomical, pathological and pathogenetic features. However, those 
describing clinical manifestations are the most widely used. Thomas
24
 proposed a 
classification system based on a combination of anatomical site and clinical findings. 
According to this classification, diabetic neuropathy is not a sole condition but 
collectively describes a number of disorders affecting peripheral nerves. Chronic 
sensori-motor neuropathies are the most common neuropathy types encountered in 
diabetes.
15
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Methods of assessing diabetic peripheral neuropathy 
Examination of DPN can be performed using a range of methods, incorporating tools as 
simple and inexpensive as a tuning fork, through to sophisticated electrophysiological 
nerve conduction equipment and associated techniques. Symptoms of pain and 
sensation loss can be assessed using a range of questionnaires. 
25
 
26
 One clinical 
measurement of neuropathy utilises a relatively simple protocol for evaluating sensory 
deficits. This procedure is a composite known as the Neuropathy Deficiency Score 
(NDS); it assesses a number of sensation modalities such as temperature, vibration and 
touch sensitivity as well as looking at distal tendon reflexes.
25
 The Semmes-Weinstein 
monofilament also investigates touch sensitivity and is another simple screening device 
designed to detect advanced neuropathy and hence those at risk of ulceration.
15
 
Quantitative sensory testing (QST) is an established, less subjective method of 
evaluating responses to vibrating and thermal stimuli and for determining sensation and 
pain thresholds; it can be applied at a number of anatomical sites but is commonly used 
on the feet in people with suspected DPN (Fig. 2).
11
 Electrophysiological nerve 
conduction studies evaluate factors such as conduction velocity, response amplitudes, 
and latencies for major peripheral sensory and motor nerves in order to define damage 
and the rate of progression of neuropathy (Fig. 3).
27
 Electrophysiological assessment is 
considered precise and objective; however it does not assess damage to small fibres.
28
 
Additionally, the procedure is uncomfortable to undergo. Skin and nerve biopsies are 
considered to be an accurate and early diagnostic tool for peripheral neuropathy. These 
procedures, however, are invasive, painful, and may be associated with subsequent 
infection in the sampled area.
11
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A novel ophthalmic marker of diabetic neuropathy 
The cornea is the most densely innervated tissue in the human body.
1
 It contains C and 
Aδ sensory fibres arising from branches of the trigeminal nerve, and it has recently 
become a focus in neuropathy studies as a prospective ophthalmic marker of DPN. 
Corneal confocal microscopy (CCM) is a recently developed, sophisticated method of 
imaging the corneal sub-basal nerve plexus, which occurs as a monolayer at the level of 
Bowman’s membrane.29 CCM is capable of detecting changes in nerve fibre density and 
branching at early stages of diabetic neuropathy in a non-invasive manner.
1, 11
 It has 
been demonstrated that corneal nerve fibre density is reduced in people with diabetes 
when compared with healthy controls, and this nerve density reduction is associated 
with the severity of neuropathy.
1
 One CCM study has shown that pancreas 
transplantation can lead to evidence of small fibre repair in people with DPN, 
suggesting that neuropathy may be reversible with improvement in blood glucose 
status.
30
 Corneal sensitivity has also been explored as a means of assessing corneal 
structure-function relationships; reduced corneal sensitivity also appears to be related to 
the severity of diabetic neuropathy.
31
 An example of a CCM image is shown in figure 4. 
 
“Insert Figure 4 here” 
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The lower limbs are the most evident focus for DPN, particularly given the fibre-length 
dependant nature of neuropathy, but nerves anywhere in the body can theoretically be 
damaged by an underlying metabolic abnormality. However, it is not well understood 
whether nerve changes in one part of the body accurately predict what is happening 
elsewhere. In the eye, the cornea and the retina are richly endowed with sensory nerve 
cells and their axons, and are therefore potential sites for neuropathy-related damage. 
This review is primarily concerned with changes to visual function and associated 
anatomical structures, and, as such will concentrate predominantly on putative effects 
on nerves comprising the retina and visual pathways. 
 
Anatomy of the retina 
The retina is a ten-layered sensory tissue forming the internal layer of the posterior 
eye.
32
 It is the entry point for processing of visual information and, as such, much of its 
volume consists of neural elements, although it also contains glial and vascular 
components. The retina is extremely metabolically active and consumes the highest 
percentage of oxygen per weight of any human tissue.
33
 Figure 5 shows a schematic of 
the retina. 
 
“Insert Figure 5 here” 
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The retina houses complex connectivity networks but, in a conveniently over-simplified 
model, its neural components can be categorized into three broad groupings. Firstly, 
photoreceptors comprise the neural elements of the outer retina. These cells are 
specialized for converting light energy to nerve impulses. The two photoreceptor types 
are rods and cones, which have an approximate population ratio of 20:1.
32
 Secondly, the 
centrally located plexiform and nuclear layers comprise several distinct neuronal cell 
types. Bipolar cells in these layers act as afferent connectors between the photoreceptors 
and the ganglion cells of the inner retina.
34
 Horizontal cells are inter-neurons that run 
parallel with the retinal surface. They are associated with rods and cones via their long 
and short processes respectively. Amacrine cells are also inter-neurons that play an 
integrative role in retinal circuitry, synapsing with bipolar and ganglion cells. They have 
large cell bodies and no true axons. Finally, the third grouping comprises retinal 
ganglion cells (RGC) and their long axons, which form the retinal nerve fibre layer 
(RNFL) and eventually the optic nerve; these are the neural components of the inner 
retinal layers. Ganglion cells relay partially processed visual information from the retina 
to the lateral geniculate nucleus (LGN). The RNFL is discussed in more detail below. 
 
In addition to these neural cells, the retina contains glial and vascular tissue. Mϋller 
cells are the principal glial cells of the retina and they serve a role similar to that of 
astrocytes in the CNS. They span the entire retina radially and their functions include 
structurally supporting the retina, providing nourishment for neural cells and assisting 
regulation of retinal blood flow.
35
 The central retinal artery (CRA), which arises from 
the ophthalmic artery, gives rise to the inner retinal vascular network that nourishes the 
anterior two-thirds of the retina. The choriocapillaris, located outside the retinal pigment 
13 
 
epithelium (RPE), provides a blood supply for the remaining third.
32
 The blood-retinal 
barrier, which is jointly achieved by the RPE and by tight junctions between retinal 
vascular endothelial cells, protects the neural retina from large molecules and toxic 
substances while permitting diffusion of essential nutrients. 
 
Retinal nerve fibre layer  
The retinal nerve fibre layer (RNFL) comprises unmyelinated axons of ganglion cells as 
well as astrocytes, Muller cell end feet and vasculature. 
36
 The fibres converge in a 
unique pattern to eventually form the optic nerve,
32
 where they exit the eye. The RNFL 
is responsible for carrying visual information directly to the lateral geniculate nucleus 
(LGN) where the majority of axons first synapse. These axons are myelinated posterior 
to the lamina cribrosa. The fibres originate from a range of locations in the retina and 
their spread-pattern is specifically dependant on this location.
37
 For example, fibres that 
originate from the foveal area find a relatively direct path to the optic nerve head, while 
those arising temporal to this need to execute a path around the putatively earlier-
developing ones (Fig. 6). This model neatly accounts for the well-described arcuate 
conformation of the RNFL in this region.
38
 A number of glaucoma studies have pointed 
out the utility of modelling axon growth as a means of describing the relationship 
between nerve fibre location and the function these fibres subserve.
39-41
 Clinical 
evaluation of RNFL patency and determination of RNFL thickness is of great 
importance in glaucoma and may yet prove to be of interest in diabetes, even though the 
patterns of change and the aetiology may in fact be substantially different between the 
two diseases.   
14 
 
 
“Insert Figure 6 here” 
 
There is substantial variation in RNFL thickness in a normal, healthy population
42
 and a 
number of factors have been identified that appear to account for at least some of this 
variance. Several studies have shown a relationship between RNFL thickness and age.
43-
45
 Histological counts of optic nerve fibres in post-mortem eyes have shown a loss of 
4000-5000 fibres per year.
46
 Other studies have reported an age-related decline in RNFL 
thickness using scanning laser polarimetry (SLP) with one reporting a loss of 7.6% per 
decade
42
 and another reporting 0.39 µm per year.
43
 Optical coherence tomography 
(OCT) has been used to show thinning of the RNFL with increasing age, particularly in 
the temporal area around the optic nerve head.
47-49
 One OCT study reported that RNFL 
thickness decreased globally about 2.6 – 2.9 µm per decade50 while another showed that 
thickness of the superior RNFL quadrant may be selectively reduced with age.
51
 Optic 
nerve head size also has an apparent correlation with RNFL thickness (albeit at a fixed 
spatial location) with most studies finding larger optic nerve heads in conjunction with 
thicker RNFL,
48, 52
 although one study appeared to find the opposite, which may be due 
to employment of disparate techniques.
53
 RNFL thickness has been shown to have an 
inverse correlation with axial length.
48, 50
 It can also vary with ethnicity 
43, 48
 but there is 
minimal evidence of a gender difference.
48, 54
 These factors need to be considered when 
investigating the effect of diabetes on retinal morphology in general, and on RNFL 
thickness in particular. 
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Diabetes related retinal pathophysiology 
Apoptosis is a series of biochemical changes which leads to regulated cell death 
subsequent to internal cell changes that include DNA fragmentation and cell 
shrinkage.
55
 Apoptosis is believed to mediate the pathogenesis of diseases of the retina 
such as glaucoma.
56
 Neuro-degeneration in diabetes has been proposed as an underlying 
cause of retinal vascular changes, and apoptosis of retinal ganglion cells has been 
reported in post-mortem human studies and in animal models of diabetes.
57, 58
 RNFL 
thinning is a potential by-product of retinal ganglion cell apoptosis and consequent 
axonal loss. 
 
Müller cells are another potential target for apoptosis in the retina. One of the main 
functions of these cells is to biochemically support the vascular endothelial cells that 
form the inner blood-retinal barrier. Apoptosis of retinal glial cells, including Müller 
cells, can thus potentially contribute to microangiopathy, or dysfunction of small blood 
vessels, that is closely related to complications of diabetes - including retinopathy, 
neuropathy,
59
 and blood-barrier impairments. High concentration of glucose in neural 
tissue as a consequence of high blood-retinal barrier permeability, leads to impairment 
of some glial and neural cell function and hence may interrupt glucose uptake from 
retinal circulation.
60
 Müller cells also act as a transporter to remove glutamate, which is 
highly toxic to retinal neurons. There is a likelihood that impaired function of Müller 
cells in diabetic retina can cause oxidative stress,
61
 which is known to be a contributing 
factor to DPN.  
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Clinical assessment of retinal nerve fibre layer integrity 
A number of different procedures allow clinical assessment of the RNFL. These have 
historically been used to assess glaucoma risk, but are nonetheless applicable to other 
disease models. Various ophthalmoscopy techniques can be used to assess RNFL 
integrity, although decisions regarding the existence of and, in particular, the 
progression of suspected pathological damage based on ophthalmoscopy alone are 
highly subjective. The development of ocular fundus photographic techniques improved 
this situation by allowing a permanent objective record for future comparison. However, 
photographic assessment also largely relies on qualitative judgement. Hoyt et al
62
 used 
red-free photography to evaluate diffuse and local loss in the peripapillary retina and 
described the fundoscopic signs of early RNFL loss in glaucoma. This method of 
photography was further developed using black and white negatives.
63
 Other groups 
enhanced red-free photographs of the RNFL using computer programmes 
64
 or used an 
image analyser to measure grey levels in red-free photographs for normal and 
glaucomatous eyes.
65
 Yamazaki et al
66
 eventually developed an analysis programme to 
detect changes of RNFL at early stages of glaucoma. Photographic assessment 
techniques can be limited by pupil size and by the presence of media opacities, as well 
as by the contrast-processing capability of the camera and associated software.  
 
The application of laser-based techniques for imaging retinal tissue commenced with 
the development of scanning laser ophthalmoscopy. This instrument afforded 
advantages over photography such as improved resolution, the ability to be applied in 
the presence of media opacities,
67
 and accompanying quantitative software analysis 
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packages.
68, 69
 However, it also introduced relative disadvantages such as the inability to 
represent true fundus colour information. More recently evolved confocal scanning laser 
ophthalmoscopes (CSLO) and associated software have allowed an indirect measure of 
RNFL thickness at the optic nerve head margin, and generated a range of two and three-
dimensional topographic features, many of which have demonstrated commendable 
reproducibility.
70
 Scanning laser polarimetry (SLP) is another imaging technique that 
has been shown to successfully use RNFL information to discriminate between healthy 
and glaucomatous eyes.
71, 72
 SLP employed a novel imaging principle to generate 
quantitative information regarding RNFL integrity. This method was based on an 
assumption that the RNFL is a birefringent (referring to multiple direction-dependent 
refractive indices) medium; this property affects the polarisation characteristics of a 
laser beam that is reflected from the retina.
71
 
 
Optical coherence tomography (OCT) arguably provides the most direct measure of 
RNFL thickness of the established retinal imaging techniques. It is a non-invasive and 
reliable technique for quantitative analysis of axial retinal morphology in multiple 
planes.
73
 OCT uses low-coherence interferometry and is comparable to ultrasonic echo 
techniques, except that light is used instead of sound. The latest generation OCT 
techniques (fourier-domain technology) have shown improved diagnostic capacity for 
monitoring retinal pathologies by capturing higher resolution images (5 µm axially) 
with a more rapid acquisition time (65 times faster than time-domain technology) 
compared with their predecessors.
74, 75
 This has enabled improved identification of 
individual retinal layers, including the RNFL, with minimal intrusion of eye movements 
18 
 
on accuracy and repeatability.
76
 The precise optical principles of OCT are outside the 
scope of this review; they have been described in detail elsewhere.
77, 78
  
 
OCT has been used widely in identifying pathologies that are known to impact on 
retinal morphology. OCT algorithms calculate retinal thickness based on the reflectivity 
of each individual layer.
77
 A standard circumpapillary OCT image, available on most 
commercially available instruments, is acquired using a cylindrical scan pattern of 3.4 
mm diameter around the optic nerve head, and the analysis is displayed as 12 position 
sectors around the disc in a manner resembling a clock. The graphical figure of RNFL 
thickness is often referred to as temporal-superior-nasal-inferior-temporal (TSNIT) or a 
“double-hump pattern”79 with the inferior quadrant having, on average, the greatest 
thickness followed by superior, nasal and temporal quadrants (Fig. 7).  
 
“Insert Figure 7 here” 
 
Evaluation of retinal nerve fibre layer in diabetes 
Examination of the retinal nerve fibre layer (RNFL) has proven useful in identifying 
axonal loss prior to visual field abnormalities becoming evident.
48
 The RNFL has been 
the focus of many glaucoma studies, given that changes in the thickness of this layer has 
become an important factor in diagnosis of the pathology.
49
 However, RNFL 
morphology and its relationship to DPN may also be of interest. Although a potential 
relationship between the presence of retinal microvasculopathy in diabetes and severity 
19 
 
of DPN has been suggested,
80
 a clear link between retinopathy and DPN has not yet 
been established and only a limited number of studies have investigated this 
relationship.
80, 81
 Given that nerve damage in diabetes can be caused by a variety of 
mechanisms, including hypoxia, oxidative stress and changes to the polyol pathways,
15
  
it is reasonable to question whether such mechanisms can also damage the RFNL and, if 
so, whether RNFL changes can predict distal neuropathy elsewhere in the body.  
 
Chihara et al
82
 measured RNFL thickness in 137 patients with Type 2 diabetes. They 
used green filtered achromatic photographic negatives to assess the nerve layer, and 
they classified retinopathy into 4 groups with level 1 showing no vascular pathology, 
and other levels representing increasing stages of retinopathy. Their results showed that 
20% of patients classified as having no retinopathy had RNFL defects and they 
suggested that the severity of retinopathy was a potential risk factor for a RNFL defect. 
They also suggested that cotton-wool spots, which generally occur in more advanced 
stages of retinopathy, are likely to cause retinal nerve fibre layer defects.  
 
Lopes de-Faria et al
83
 conducted quantitative assessment of RNFL thickness, using SLP 
in a small sample (N=10) with Type 1 diabetes. Their results showed, when compared 
with controls, a significant reduction in mean RNFL thickness in the superior quadrant 
for a cohort with diabetes who had no ophthalmoscopically evident retinopathy.
83
 
Another study by Skarf et al
84
 found similarly. Sugimoto et al
85
 were one of the first 
groups to evaluate RNFL thickness in people with diabetes using OCT. Their results 
showed a general reduction in RNFL thickness in all quadrants for a diabetic cohort 
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without evident retinopathy but the reduction was more significant superiorly, in 
agreement with earlier SLP findings.
83
 Each of these studies suggested that impaired 
vasoconstriction processes in the superior quadrant, secondary to diabetes, may best 
explain the RNFL loss in this region. In contrast, a recent OCT study failed to find a 
significant difference in RNFL thickness between a diabetic group without retinopathy 
and controls, even though the diabetic group demonstrated comparatively reduced 
RNFL thickness globally and in all quadrants.
86
 Their findings did, however, show that 
reduction in RNFL thickness was more evident in proliferative rather than earlier stages 
of retinopathy, and that RNFL thickness changes correlated with longer duration of 
diabetes.  The authors also suggested that diabetes-related RNFL damage may develop 
more rapidly in men than in women, but they did not propose a specific mechanism for 
this finding.   
 
Evaluation of visual function in diabetes 
Diabetic retinopathy is a major cause of blindness in developed countries; as such, 
diagnosis and intervention prior to the onset of sight threatening vascular complications 
is crucial.
87
 Assessment for retinopathy, in line with Early Treatment for Diabetic 
Retinopathy Study (ETDRS) recommendations, has focused on the progression of 
retinal vascular changes, from background through to proliferative stages of the 
disease.
88
 The majority of published work on the retina in diabetes has investigated the 
effect of vascular changes on visual function; 
88-90
 however, several studies have shown 
visual function deficits in eyes that have normal visual acuity and minimal evidence of 
diabetic retinopathy.
91, 92
 Bresnik et al
93
 argued strongly that retinopathy should not be 
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viewed as a vascular pathology in isolation and that a similar argument can be applied 
to neuropathy; it should not be considered as isolated  neural disease. Anatomical and 
physiological changes to the retina in diabetes highlight the importance of considering 
neural and vascular complications as potentially linked processes.   
   
The electroretinogram (ERG) has been used to investigate functional and (presumed) 
biochemical changes at a retinal level.
94, 95
 There are different types of ERG. Full-field 
(flash) ERG is the basic method of recording massed retinal electrical response to light 
stimulation and it separates photoreceptor from inner retinal responses by isolating a 
number of recognisable waveforms. Pattern ERG (PERG) stimulates the retina using 
patterned stimuli such as checkerboards, and specifically investigates the activity of 
ganglion cells and associated structures. Multifocal ERG (mfERG) evaluates small 
areas of retina individually and is valuable for assessing diabetic-related retinal changes, 
such as cotton-wool spots, that may affect visual function in spatially localised 
patches.
96
 
 
There is evidence that ERG signals are impaired in diabetes prior to the onset of 
clinically evident retinopathy.
97, 98
 Papakostopoulos et al 
99
 reported decreased ERG b 
wave amplitude in a Type 1 diabetic cohort without evident retinopathy. Di Leo et al
100
 
and Caputo et al
101
 each found reduced PERG amplitudes in diabetic subjects without 
retinopathy. Multifocal ERG has also been used to demonstrate early functional changes 
in diabetes.
102, 103
 Significant reductions in the direct response amplitude and implicit 
times in diabetic patients with no evidence of retinopathy have been reported.
104, 105
 
Lovasik and Spafford
106
 as well as other studies
107, 108
 have shown changes to the 
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amplitude or onset of oscillatory potentials (OP) in diabetes in the absence of 
retinopathy. OP wave components are believed to originate from inner retinal layers 
through the activity of amacrine cells.
109, 110
 
 
Visual evoked potentials (VEP) represent electrical responses to counter-phasing visual 
stimuli (for example, checkerboard patterns). They can provide diagnostic information 
about visual pathway integrity or neuro-sensory disorders beyond the retina. The most 
commonly analysed response to visual stimuli is termed the P100, in which a 
recognisable peak of electrical activity occurs approximately 100 milliseconds after 
stimulus onset. Alterations to expected latency and waveform of the P100 can be 
indicative of visual pathway pathology. Non-visual event-related potentials can also be 
employed to investigate a range of sensory and executive functions. The P300 (also 
referred to as the cognitive potential) represents an activity peak that occurs 
approximately 300 milliseconds after the onset of non-specific task-related change.
111
 
 
VEP latencies have been investigated in people with diabetes and P100 latency has been 
proposed as a potential method for assessing neuropathy of the central nervous system 
in people with diabetes.
112
 Studies have shown significant increases in P100 latency in 
diabetic groups compared with controls.
113-116
 A positive relationship between 
peripheral nerve conduction and P100 latency in the absence of retinopathy has 
suggested a potential effect of neuropathy on optic pathways.
114
 One study using P300 
found prolonged latencies related to diabetes in people with normal cognitive function 
and no retinopathy.
117
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Very few studies have investigated the ability of commercially available standard (white 
on white) visual field tests to detect contrast sensitivity changes in diabetic individuals. 
Early investigations related to this relied on manual perimetry techniques. Roth et al
118
 
examined the effect of diabetes on visual fields using a home designed “scotometer”. 
Their findings suggested that the existence of a scotoma in the central 20 degrees could 
be an early indicator of retinal compromise in patients with no visible ophthalmoscopic 
signs. Wisznia et al
119
 studied visual field defects at various stages of retinopathy using 
Goldman perimetry. They showed a partial constriction of the central isopter in diabetic 
patients with non-proliferative retinopathy. However, there is evidence that manual 
perimetry does not always effectively detect a visual field deficit, even in the presence 
of significant loss of neural cells.
120
  
 
The evolution of static automated perimetry enabled quantitative analysis of contrast 
sensitivity for a well defined grid of test points, improving the potential for visual field 
analysis techniques to detect earlier, spatially specific changes in visual sensitivity.
120
 
Trick et al 
121
 used automated visual field assessment to examine visual sensitivity in a 
cohort of people with diabetes who had either no vascular changes, or had mild back 
ground retinopathy only. Their findings showed significantly higher pattern deviation 
and lower mean deviation values for diabetic participants than for age-matched controls.  
Subgroup analysis revealed that the mean deviation in both groups was dependent on 
the level of retinopathy. Bell et al
122
 found isolated loss of sensitivity in the central 15 
degrees of visual field in a diabetic group with normal retinal perfusion; they suggested 
that the loss may have been caused by  microangiopathy and may further reflect retinal 
glial deficits. Several studies have compared the efficacy of short-wavelength 
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automated perimetry (SWAP) and standard, white-on-white techniques for the detection 
of early psychophysical abnormalities in diabetes.
123, 124
 Findings from these studies 
tentatively suggest that SWAP has the better potential to detect early functional 
changes. 
 
Flicker sensitivity describes an observer’s ability to detect intermittent light and dark 
alternation of a visual stimulus. It has been suggested that rapidly flickering stimuli are 
preferentially perceived by the magnocellular pathway;
125, 126
  this pathway is 
characterized by fast conduction velocity, sensitivity to high temporal frequency 
stimuli, and the ability to detect movement.
127
 Flicker ERG has been used to 
demonstrate impaired retinal sensitivity in diabetes.
128
 Lobefalo et al
129
 investigated 
flicker sensitivity in the central 30 degrees of visual field in a cohort with diabetes who 
had no clinical signs of retinopathy. They examined a group of children with Type 1 
diabetes divided in two groups according to their metabolic control (good and poor). 
Results indicated that mean flicker fusion frequency values for both diabetic groups 
were significantly lower than age-matched controls and were also highly related to the 
degree of metabolic control. The authors suggested that the presence of flicker 
impairment in the absence of clinically detectable retinopathy and media opacities could 
be a result of diabetes-related RNFL abnormalities.
129
 
 
Stavrou and Wood
130
 evaluated flicker sensitivity in the central visual field for a group 
with Type 2 diabetes and compared these findings with results obtained from standard, 
white-on-white perimetry. The majority of defects detected by flicker perimetry 
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appeared in the central 6 degrees of visual field, while defects shown by the standard 
technique were located more towards the periphery. In another recent study, Zele et al
131
  
found sensitivity losses using red-on-white and white-on-white flickering and static 
stimuli across the central visual field in a diabetic cohort, compared with age-matched 
controls. The authors suggested that red-on-white perimetry is more capable of 
detecting deeper defects than the standard white-on-white technique.   
 
Metabolic control of diabetes is believed to have an impact on flicker perception. It has 
been demonstrated that a flicker stimulus increases capillary blood flow by 30%. This 
blood flow increase is maximal in peri-foveal areas where ganglion cell density is 
highest. This could indicate that a tight link exists between the microvasculature 
arrangement and areas in the retina with high metabolic demand.
132
 Mandecka et al
133
 
suggested that a flickering stimulus causes vasodilatation and showed that the 
vasodilatation response to flicker is diminished before retinopathy is clinically 
manifested.  It has been shown that retinal blood vessels do not have a conventional 
autonomic innervation despite relevant receptors in the walls of these vessels.
134
  
 
Frequency doubling technology (FDT) perimetry has been shown to be a useful 
predictor of early visual loss in glaucoma.
135
 Frequency doubling occurs when a low 
spatial frequency sinusoidal grating undergoes a high temporal frequency counter-phase 
flicker; the theory underlying frequency doubling has been described in detail 
elsewhere.
136
 The perception of this phenomenon is thought to be mediated primarily by 
the magnocellular visual pathway.
136
 Parikh et al
137
 demonstrated that FDT could 
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differentiate between diabetic patients with and without retinopathy, but it demonstrated 
poor predictive capability for macular oedema. Parravano et al 
138
 also examined the 
role of FDT in eliciting early field defects  in people with Type 1 diabetes. They 
suggested that reductions in retinal sensitivity in people with diabetes might relate to 
magnocellular pathway dysfunction, indicating that this pathway may be more 
susceptible to damage under hyperglycemic conditions. However, they acknowledged 
that this may alternately represent the capacity of the less populated parallel pathway to 
detect earlier functional loss. The authors further suggested that these visual function 
changes may be a result of neural loss, implying that neuropathy, rather than 
vasculopathy, is the primary underlying mechanism. Table 2 represents a summary of 
the findings of key retinal and functional studies with potential neuropathy-related changes. 
 
Other measurements of visual function 
Impaired colour vision has been reported to be an early sign of visual function loss in 
diabetes.
139, 140
 Acquired blue-yellow losses using the Farnsworth-Munsell 100 Hue 
(FM100) test in a diabetic cohort have been reported to occur before the onset of 
retinopathy.
141, 142
  Hardy et al
143
 found abnormal colour vision using FM100 in 57% of 
a cohort who had no evidence of microvascular disease of the retina. Roy et al 
144
 also 
reported colour vision losses in a group of people with diabetes who had minimal 
retinopathy. These findings suggest that colour discrimination losses in diabetes may 
not necessarily be of vascular aetiology.  
Contrast sensitivity measurements can elicit defects that are not readily detectable by 
commonly employed conventional clinical techniques, such as visual acuity.
91
 Changes 
in contrast sensitivity, some of which are spatial frequency dependent, have been 
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demonstrated in both children and adults with diabetes. Della Sala et al 
91
  demonstrated 
contrast sensitivity changes up to two standard deviations below normal values in a 
diabetic cohort, compared with age-matched controls. Ghafour et al
145
 reported 
increased contrast thresholds at high spatial frequencies in people with diabetes without 
clinically evident retinal vascular changes. Another group also found a reduction in 
contrast sensitivity in patients with early diabetic retinopathy.
146
 The impact of 
metabolic control of diabetes on contrast sensitivity has also been investigated.  Di Leo 
et al
147
 suggested that, rather than hyperglycaemia, repeated hypoglycaemia events may 
be more important factors in the pathogenesis of neuronal damage. Ewing et al
148
 also 
found contrast sensitivity losses during hypoglycaemic events in subjects with Type 1 
diabetes who had no evidence of retinopathy. The authors suggested that 
hypoglycaemic related neural damage may be associated with increased “neural noise” 
at retinal and brain levels.
149
  
 
Other psychophysical measurements such as dark adaptation have also been 
investigated in diabetes,
150-152
 although a number of groups have focused primarily on 
post-photocoagulation outcomes.
153, 154
 Some findings however, have suggested that 
longer dark adaption times occur in diabetes and that final adaptation thresholds are 
higher than age-matched norms.
152
 A recent study reported that adaptation changes are 
related to retinopathy levels but could be observed before the onset of vascular 
changes.
155
 This provides further evidence that changes to visual sensitivity in diabetes, 
prior to clinical manifestation of retinopathy, may relate to neuropathy. Other studies 
have used techniques such as flavoprotein autofluorescence, macular photostress test 
and electroocculogram to demonstrate changes to visual function related to diabetes or 
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to sudden blood glucose spikes in healthy individuals. 
156-158
  However these outcomes 
have been attributed to retinal pigment epithelium function or metabolic tissue stress 
and are less likely to be strictly aligned with peripheral neuropathy. 
 
Summary and conclusion 
Neuropathy is a major complication of diabetes, and is known to have widespread 
impact on many vital organs of the body. Furthermore, at least fifty percent of 
individuals with diagnosed diabetes will eventually suffer from peripheral neuropathy, 
which is a major risk factor for foot ulceration and amputation. The establishment of 
earlier, safe, non-invasive and less painful diagnostic tools to determine the presence 
and severity of neuropathy needs to be a research priority. Eye-care professionals who 
provide care for people with diabetes understandably focus on vascular aspects of the 
disease. However, emerging evidence that corneal nerve structure is a potential marker 
of early peripheral neuropathy has introduced the prospect of a new and important role 
for eye care professionals in the management of diabetes. Retinal anatomy and visual 
function markers similarly have potential to contribute to this process; demonstrated 
structural and functional changes in diabetes prior to the development of retinopathy can 
reasonably be presumed to be neuropathic in origin. However, it is yet to be established 
whether these factors will prove to be clinically useful predictors of diabetic peripheral 
neuropathy. 
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Table 1. Classification of peripheral nerve fibres. † Source of skeletal muscle contraction, ‡ 
Controlling muscle spindle sensitivity, ¶ visceral sensory fibres, ŧ Less myelinated than A and C 
fibres. (derived from reference 16 with modification) 
Source 
 
Classification Myelination Diameter (µm) Conduction 
velocity (m/s) 
Efferent 
α-motoneurons to 
muscles  † 
Aα Yes 8 - 13 44 -78 
γ-motoneurons to 
muscles ‡            
Aγ Yes 3 - 8 18 - 48 
Preganglionic 
autonomic fibres ¶     
B Yes ŧ < 3 3- 14 
Afferent 
Limb position and 
motion                
Aα Yes 12 - 20 75 - 120 
Touch, pressure, 
vibration 
Aα / Aβ Yes 6 - 12 30 - 75 
Sharp pain, cold 
sensation             
Aδ Yes 1 - 6 5 - 30 
Dull pain, warm 
sensation              
C No < 1.5 0.5 - 2 
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Method 
 
Study Finding 
 
Visual field 
studies 
Roth et al 1969 
 
 
 
Trick et al 1990 
 
 
 
 
Afrashi et al   2003 
 
 
 
 
Lobefalo et al 1997 
 
 
 
 
 
Stavrou and Wood 2005 
 
 
Central 20 degree scotoma occurs prior to 
diabetic retinopathy development 
 
 
Contrast sensitivity reduction in superior 
quadrant for T2DM cohort with minimal 
or no retinopathy 
 
 
Blue on yellow perimetry finds sensitivity 
reductions not evident in standard 
perimetry for T1DM cohort without 
evident retinopathy 
 
 
Flicker sensitivity reduced in central 30 
degrees of visual field for T1DM cohort 
without angiographic evidence of 
retinopathy 
 
 
Flicker but not static perimetry thresholds 
reduced in T2DM cohort with minimal 
retinopathy 
 
Retinal nerve fibre 
layer (RNFL) 
studies 
Sugimoto et al 2005 
 
 
 
 
Takahashi et al 2006 
(159) 
 
Lopes de Faria et al 2002 
Decreased superior RNFL thickness 
(OCT) for T2DM cohort without evident 
retinopathy 
 
Decreased RNFL thickness (SLP) for 
T2DM cohort with mild retinopathy 
 
Decreased superior RNFL thickness (SLP) 
for T1DM cohort without evident 
retinopathy 
 
 
 
 
Electrophysiological 
visual function 
studies 
Lovasik and Spafford 
1988 
 
 
Papakostopoulos et al. 
1996 
 
 
Yaltkaya et al 1988 
 
ERG b wave and oscillatory potentials 
altered for T1DM cohort without evident 
retinopathy 
 
Decreased ERG b wave amplitude in 
T1DM cohort without evident retinopathy 
 
VEP P100 latency prolonged in cohort 
with diabetes but no evident retinopathy 
 
Table 2. Summary of the findings of key retinal and functional studies with potential 
neuropathy-related changes. T1DM: Type 1 diabetes mellitus, T2DM: Type 2 diabetes 
mellitus, OCT : optical coherence tomography, SLP: scanning laser polarimetry, ERG: 
electroretinogram, VEP: visual evoked potential 
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Figure 1. An illustration of interaction between the central nervous system and the peripheral 
nervous system (courtesy of Kimball's Biology Pages (http://biology-pages.info), February 
2010, with modification) 
 
Figure 2. Quantitative sensory testing unit (left) featuring vibration and thermal modalities. 
Outcome-based colour graphic reports (right) with automated narrative discussion of test results 
(from Medoc Ltd 2007 website http://www.medoc-web.com/medoc_en_home.aspx)  
 
Figure 3. Electrophysiology test of the peroneal nerve 
 
Figure 4. Corneal confocal microscopy image of a diabetic cornea (right) and normal cornea 
(left)  
 
Figure 5. Illustration of the retina showing retinal layers (left) and specific neural components 
(right) 
 
Figure  6. RNFL unique spread pattern 
 
Figure 7. OCT retinal nerve fibre layer histogram illustrating a double hump pattern (courtesy of 
Optovue RTVue™). TSNIT (temporal-superior-nasal-inferior-temporal) 
 
